Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
4(80%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed120%
terminated480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

NCT05741346
terminatedphase_2

A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04702568
terminatedphase_2

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

NCT05116774
terminatedphase_2

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

NCT05162066
completedphase_1

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

NCT04330534

Clinical Trials (5)

Showing 5 of 5 trials
NCT05741346Phase 2

Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Terminated
NCT04702568Phase 2

A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated
NCT05116774Phase 2

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated
NCT05162066Phase 2

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

Terminated
NCT04330534Phase 1

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5